{"filings":[{"id":1415116,"accession_number":"0001104659-26-080325","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2026-07-02T20:10:37+00:00","items":["1.01","9.01"],"status":"ready","headline":"BNB Plus Corp. amends Registration Rights Agreement to extend Filing Date","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment extends Filing Date to 30 calendar days after Final Closing Date, which must occur on or before July 17, 2026.","Amendment entered into with purchasers holding 50.1% or more of Registrable Securities.","Counterparties include Comstock Multichain Fund and KGPLA Holdings LLC.","Amendment dated June 23, 2026, and reported on Form 8-K on June 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1277436,"accession_number":"0001104659-26-077784","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K/A","filed_at":"2026-06-25T20:26:28+00:00","items":["3.02"],"status":"ready","headline":"BNB Plus raises $4.3M via private placement of preferred stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed Inducement Agreements with three investors on June 23-24, 2026, issuing 1.32M Series B-1, 1.20M Series B-2 Preferred, and warrants for 2.30M B-2 shares for $1.54M.","Entered two more Inducement Agreements on June 10, expected close by July 1, issuing 192k Series B-1 and 511k Series B-2 Preferred for ~$0.22M.","Aggregate across all agreements: 3.89M Series B-1, 1.71M Series B-2, and warrants convertible into ~7.9M common shares for $4.3M gross proceeds.","Securities issued under Section 4(a)(1) and Rule 506(b) exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":833963,"accession_number":"0001104659-26-070110","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K/A","filed_at":"2026-06-03T20:13:31+00:00","items":["3.02"],"status":"ready","headline":"BNB Plus raises $2.5M via preferred stock/warrants, additional $0.22M from inducement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed SPA on May 28: issued 2,380,953 Series B-1 Preferred shares and Common Warrants at $1.05/share, gross proceeds $2.5M.","Entered Inducement Agreement on May 31 for Series E warrant exercise of approximately $0.22M.","Initial closing of inducement agreements (May 26 & May 31) expected by June 9 with aggregate gross proceeds ~$1.72M.","Securities issued under Section 4(a)(1) and Rule 506(b) exemptions; not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":677876,"accession_number":"0001104659-26-066610","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2026-05-27T12:15:32+00:00","items":["1.01","5.03","3.02","3.03","7.01","9.01"],"status":"ready","headline":"BNB Plus Corp. raises up to $5M in convertible preferred equity private placement and warrant inducement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial SPA closing of $2.5M expected May 28; Series B-1 Preferred (8% dividend) and Common Warrants ($0.76 strike) issued.","Series E warrant exercise by existing holders of ~$1.65M; exchange for Series B-2 Preferred (6% dividend); closing by June 2.","First $2.3M of proceeds used for biotech strategic review and corporate purposes; excess to digital asset treasury subsidiaries.","Series B-1 and B-2 Preferred created, each initially convertible 1:1 into common stock with senior liquidation preferences.","Registration rights agreement filed within 30 days; resale registration to cover Preferred Shares, warrant shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98647,"accession_number":"0001104659-26-051503","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BNB Plus stockholders approve reverse stock split authorization (1:5 to 1:30)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vote: 2,420,538 for, 317,840 against, 11,866 abstained on reverse split proposal.","Board granted 12-month discretion to set ratio between 1-for-5 and 1-for-30.","Number of authorized common shares to remain unchanged after split.","Adjournment proposal also approved (2,400,755 for, 314,899 against, 34,590 abstained)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114249,"accession_number":"0001104659-26-033842","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BNB Plus receives Nasdaq delisting notice for bid price non-compliance; ineligible for grace period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BNB Plus on March 20, 2026 that its stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Mar 19.","Company is ineligible for a compliance cure period due to reverse stock splits in prior two years with cumulative ratio of 250:1 or more.","BNB Plus intends to timely request a hearing before Nasdaq Hearings Panel, which will automatically stay any suspension or delisting pending the process.","There is no assurance the Panel will grant continued listing or that the company can regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114248,"accession_number":"0001104659-26-010893","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BNB Plus appoints digital asset veteran James Haft as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Haft appointed to board and Nominating Committee effective Feb 2, 2026.","Haft brings over 35 years experience in blockchain, digital assets, and traditional finance.","Compensation includes $40,000 cash fee and option grant of 93,000 shares at $1.31/share vesting over one year.","Appointment aims to support BNBX's treasury operations and DeFi yield generation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114247,"accession_number":"0001104659-26-005784","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Elizabeth M. Schmalz Shaheen resigns from BNB Plus board effective Jan. 15, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elizabeth M. Schmalz Shaheen resigned as director of BNB Plus on January 15, 2026.","Resignation was immediate; not due to any disagreement with the company.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130623,"accession_number":"0001104659-25-120899","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BNB Plus stockholders approve increase in authorized shares to 500M and amend equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to authorize exercisability of pre-funded warrants and issuance of underlying common stock passed with 1,642,390 votes for.","Amendment to Certificate of Incorporation increasing authorized common stock from 200M to 500M approved (1,971,926 for).","Amendment to 2020 Equity Incentive Plan to reserve an additional 5,000,000 shares approved (1,613,405 for).","All three proposals passed at special meeting on December 12, 2025; broker non-votes were present on two proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130622,"accession_number":"0001104659-25-113218","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Applied DNA rebrands to BNB Plus Corp., appoints Josh Kruger as Board Chairman","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed to BNB Plus Corp. effective Nov 13, 2025; ticker remains BNBX on Nasdaq.","Josh Kruger appointed Chairman of the Board; Judy Murrah steps down as Chairperson but stays as director.","Rebrand aligns with a yield-optimized BNB-based digital asset treasury strategy using the Binance ecosystem.","Kruger is founder of OnChain Alpha and ex-Head of Trading at Coral Capital, acquired by DNA Fund in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130621,"accession_number":"0001104659-25-109267","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Applied DNA Sciences appoints Joshua Kruger as Chairman, replacing Judith Murrah","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective November 6, 2025; Kruger also becomes director, filling vacancy from Sanford Simon's resignation.","Kruger holds ~33% economic interest in Cypress entities providing advisory and asset management services to the company.","Strategic Advisor Agreement includes $60,000 monthly fee and warrants to purchase 1,986,634 shares issued to Cypress Management LLC.","Kruger individually purchased 75,302 shares and warrants for $250,002.64 in October 2025 private placements.","Murrah resigned as Chair but remains on board; Kruger is not independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130620,"accession_number":"0001104659-25-105945","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Applied DNA Sciences enters $8.16M ATM offering and consulting deal with Patrick Horsman","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["ATM agreement with Lucid Capital Markets for up to $8,157,932 of common stock at market prices.","Agent commission 3.0% of gross sales price; estimated offering commencement expenses ~$175,000.","Consulting agreement with Patrick Horsman effective Oct 1, 2025, requires 75% work time commitment.","Consulting agreement includes 12-month severance if terminated without cause and IP assignment to company.","Consulting references BNB digital asset strategy; no compensation amount specified in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130619,"accession_number":"0001104659-25-101630","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Applied DNA closes $27M PIPE, buys 15,555 BNB tokens, launches digital asset treasury","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$27M from PIPE, with potential additional $31M from warrant exercises.","Received $15.3M in cash/stablecoins and OBNB trust units valued at $11.71M representing 10,647 BNB tokens.","Purchased an additional 4,908 BNB tokens valued at ~$5.3M on October 20, 2025.","Streamlined operations achieving approximately $2.9M in annualized cost savings.","Company shifts to yield-focused BNB digital asset treasury strategy led by new CIO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130618,"accession_number":"0001104659-25-097097","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Applied DNA cuts 60% of workforce ($1.4M charges), ticker changes to BNBX Oct 7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduces workforce by 16 employees (~60%) with estimated pre-tax charges of ~$1.4M for severance and benefits.","Restructuring substantially complete by end of October 2025; annualized cost savings of ~$2.9M expected.","Ticker symbol changes from APDN to BNBX on Nasdaq effective October 7, 2025, reflecting BNB treasury strategy.","Company to focus on yield-generating BNB digital asset treasury and decentralized finance integration.","No stockholder action required; CUSIP and listing unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130617,"accession_number":"0001104659-25-095401","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"APDN raises $27M via PIPE for BNB treasury strategy; CEO replaced, ticker to change to BNBX","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$27M from private placement of shares & warrants; up to $58M if warrants exercised; proceeds to acquire BNB tokens.","CEO Judith Murrah resigned; Clay Shorrock (former Chief Legal Officer) appointed as President & CEO effective Sept 29, 2025.","New advisors: Anthony Scaramucci (SkyBridge), Patrick Horsman (CIO), Josh Kruger (Chairman nominee), JR Pasch.","Company to change ticker to BNBX; plans BNB treasury strategy with active DeFi yield generation via Cypress LLC.","Entered 5-year DAS with Cypress LLC (1.25% mgmt fee + 10% incentive) and advisor agreement with Cypress Management ($60k/month + 9.5% warrants)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147166,"accession_number":"0001104659-25-094465","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","3.02","5.02","8.01"],"status":"ready","headline":"Applied DNA Sciences raises $26.8M, appoints new CEO, adopts BNB treasury strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised approximately $26.8 million via private placement selling 4.73M shares and warrants at $3.82 per share.","CEO Judith Murrah stepped down on Sept 29, 2025; Clay Shorrock appointed as new CEO effective same day.","Entered strategic digital assets services agreement with Cypress LLC for discretionary management of BNB and other crypto.","Engaged Cypress Management LLC as strategic advisor with $60,000 monthly fee and warrants for 9.5% of outstanding shares.","Offered securities under Section 4(a)(2) and Rule 506(b) of Regulation D; securities are unregistered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147165,"accession_number":"0001104659-25-078611","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Applied DNA Q3 FY2025 revenue $304K, operating loss $3.7M; cash burn improves 19% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $304K (down 36% YoY from $473K); operating loss $3.7M vs $3.3M loss in prior year.","Adjusted EBITDA negative $3.9M; monthly net cash burn $934K, down 19% sequentially and 25% YoY.","Received follow-on LineaDNA order >$600K from IVD manufacturer; added new U.S. mRNA CDMO customer.","Cash and equivalents $4.7M at June 30, 2025, including $723K from warrant exercises.","Company closed MDx Testing Services (discontinued ops) and executed 1:15 reverse stock split in June."],"consensus_eps_estimate":null,"consensus_eps_actual":-256.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":1937506.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147164,"accession_number":"0001104659-25-066078","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Applied DNA regains Nasdaq minimum bid price compliance; hearing cancelled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 2, 2025, Nasdaq notified Applied DNA it regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).","The July 15, 2025 hearing before the Nasdaq Hearings Panel has been cancelled.","Applied DNA's common stock will continue to be listed and traded on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165753,"accession_number":"0001104659-25-064106","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["2.05","5.02","7.01","9.01"],"status":"ready","headline":"Applied DNA restructures to focus on LineaRx; cuts 27% of staff, shuts clinical lab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 27% (projected 23% payroll cut); ceases operations at Applied DNA Clinical Labs.","One-time charges of ~$300k; majority of costs expected by Sept 30, 2025.","CEO Judy Murrah takes 15% salary reduction to $340k/year.","Company ends May 2025 with ~$4.8M cash; cumulative headcount reduction of 39% since Dec 2024.","Restructuring positions LineaRx synthetic DNA manufacturing as sole focus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165752,"accession_number":"0001104659-25-060258","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Applied DNA CEO James Hayward retires; President Judy Murrah named CEO and Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO and Chairman James Hayward retires effective June 18, 2025, after 20-year tenure.","Hayward receives $450,000 separation paid over 8 months; first installment by July 15, 2025.","President Judy Murrah appointed CEO, Chairperson, and Board director effective June 18, 2025.","Murrah retains $400,000 annual base salary; no additional board compensation.","Murrah previously President and COO; background includes leadership at Symbol Technologies and Motorola."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165751,"accession_number":"0001104659-25-057222","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Applied DNA Sciences receives Nasdaq delisting notice for bid price deficiency; requests hearing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified APDN on May 30, 2025 that bid price closed below $1.00 for 32 consecutive business days, violating Listing Rule 5550(a)(2).","APDN executed a 1-for-15 reverse stock split on June 2, 2025 to address deficiency, but is ineligible for a compliance period due to prior reverse splits.","Company timely requested a hearing before Nasdaq Hearings Panel on June 6, 2025, which stays any suspension or delisting pending outcome.","No assurance that the Panel will grant continued listing; shares remain at risk of delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165750,"accession_number":"0001104659-25-053914","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Applied DNA announces 1-for-15 reverse stock split effective June 2, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio set at 1-for-15; effective 12:01 a.m. ET on June 2, 2025.","Outstanding shares reduce from ~7.8M to ~519K; fractional shares rounded up to nearest whole.","Stock continues trading on Nasdaq under ticker APDN with new CUSIP 03815U607.","Split intended to bring company into compliance with Nasdaq $1.00 minimum bid price requirement.","Board approved ratio on May 27, 2025; stockholder authorization obtained at May 22 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165749,"accession_number":"0001104659-25-051992","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Applied DNA shareholders approve reverse split, warrant exercise, share increase at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected (Hayward, Catell, Ceccoli, Shamash, Simon, Shaheen) with average ~572K for vs ~117K withheld.","Ratification of CBIZ CPAs P.C. as auditor approved (2.24M for, 108K against, 14.5K abstain).","Reverse stock split authorization approved (1.71M for, 654K against) with ratio range from 1:5 to 1:50 determined by board.","Exercisability of warrants from Oct 2024 offering approved (553K for, 131K against, 1.67M broker non-votes).","Equity plan share increase by 3M shares approved (478.5K for, 208.5K against, 1.67M broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165748,"accession_number":"0001104659-25-049406","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Applied DNA Q2 fiscal 2025 revenue up 6% to $983k; net loss narrows to $3.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $983k (+6% YoY); LineaRx up 44% while MDx testing fell 33%.","Net loss $3.3M vs $4.5M prior year; operating loss $3.5M; adjusted EBITDA -$3.3M.","Cash $6.8M at quarter end; expects quarterly cash burn to decline starting June 30, 2025.","GMP Site 1 validated; annual revenue capacity $10M-$30M; new customer orders for LineaDNA.","Submitted H5N1 diagnostic validation to NYSDOH; investor call on June 3, 2025."],"consensus_eps_estimate":-38.25,"consensus_eps_actual":-33.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":2179991.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165747,"accession_number":"0001104659-25-032904","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Applied DNA Sciences regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified APDN on April 7, 2025 that compliance with Rule 5550(a)(2) is regained.","Closing bid price met $1.00 or greater from March 14 through April 4, 2025.","Deficiency matter is now closed; company remains listed on Nasdaq Capital Market.","No financial impact; stock had been at risk of delisting due to low bid price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165746,"accession_number":"0001104659-25-030551","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Applied DNA Sciences sets 2025 annual meeting for May 22; proposal deadline April 11","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 Annual Meeting scheduled for May 22, 2025, held virtually.","Record date for voting is April 3, 2025 (close of business).","Stockholder proposals under Rule 14a-8 must be received by April 11, 2025.","Director nominations and other business proposals due by close of business on April 11, 2025.","Deadline extends because meeting date changed by more than 30 days from 2024 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183339,"accession_number":"0001104659-25-022883","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Applied DNA Sciences to effect 1-for-50 reverse stock split on March 14, 2025 to meet Nasdaq bid price rule","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse split ratio 1:50; outstanding shares reduce from ~55.2M to ~1.1M.","Effective at 12:01 a.m. ET on March 14, 2025; ticker APDN unchanged; new CUSIP 03815U508.","Split intended to cure Nasdaq minimum bid price non-compliance; board approved March 3, 2025.","Fractional shares rounded up to nearest whole share; no change in par value or authorized shares.","Stockholders with street name accounts need no action; accounts adjusted automatically."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183338,"accession_number":"0001104659-25-019153","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Applied DNA Sciences special meeting fails quorum; warrant approval delayed","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Reconvened special meeting on Feb 28, 2025, had only 16,413,535 shares present, short of one-third outstanding requirement.","No action taken on proposal to approve exercise of Series C & D warrants from October 2024 offering.","Company is obligated to call another stockholder meeting to seek warrant stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183337,"accession_number":"0001104659-25-014243","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Applied DNA fails to secure quorum at special meeting; adjourned to Feb 28","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting on Feb 14, 2025 had 16,020,694 shares present, below one-third quorum requirement.","No action taken on sole proposal: stockholder approval for warrant exercise from October 2024 offering.","Meeting adjourned for second time to February 28, 2025 at 11 a.m. for further solicitation.","Without approval, warrants cannot be exercised; company obligated to call subsequent meeting if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183336,"accession_number":"0001104659-25-012921","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Applied DNA exits DNA tagging business, cuts 20% headcount; Q1 revenue $1.2M (+34% YoY), net loss $2.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.2M (+34% YoY); operating loss $3.0M vs $3.8M; net loss $2.7M vs $1.1M.","Exiting DNA Tagging segment; workforce reduction 20% (13% annual payroll cut); ~$300k severance in Q2 FY25.","GMP Site 1 completed Jan 31, 2025, ISO 7/5 certified; projected annual revenue $10M-$30M at full capacity.","Cash $9.3M as of Dec 31, 2024, includes $5.7M net from October registered direct offering.","First-in-human clinical validation of Linea DNA in CAR-T therapy under Czech regulatory approval."],"consensus_eps_estimate":-45.9,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1196617.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183335,"accession_number":"0001104659-25-007587","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Applied DNA Sciences replaces auditor Marcum with CBIZ CPAs; prior reports had going concern emphasis","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["On Jan 24, 2025, Marcum resigned as auditor; Audit Committee approved engagement of CBIZ CPAs P.C. for FY ending Sep 30, 2025.","Marcum's reports for FY 2024 and 2023 contained an explanatory paragraph regarding going concern uncertainty but no adverse opinion.","No disagreements or reportable events between the Company and Marcum during the relevant periods.","Change stems from CBIZ's acquisition of Marcum's attest business, effective Nov 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183334,"accession_number":"0001104659-25-005601","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Applied DNA Sciences special meeting lacks quorum; warrant exercise approval delayed to Feb 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Jan 23 lacked quorum; only 14,062,557 shares present, below one-third required.","No action taken on sole proposal to approve warrant exercises from Oct 2024 offering.","Meeting adjourned to Feb 14, 2025, for additional stockholder solicitation.","Company obligated to call a subsequent meeting if approval not obtained at adjourned meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183333,"accession_number":"0001104659-25-002888","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Applied DNA Sciences makes investor presentation available; no specific disclosures provided in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing reports use of a company presentation dated January 13, 2025 for investor meetings.","Presentation content is not summarized in the filing; no financial results or material events disclosed.","This is a routine Regulation FD disclosure of corporate presentation materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199924,"accession_number":"0001104659-24-129367","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Applied DNA posts FY2024 revenue of $3.4M, net loss $7.1M; announces restructuring and leadership changes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $813K (up vs $780K YoY); FY revenue $3.4M vs $13.4M; net loss Q4 $3.3M ($0.32/sh), FY $7.1M ($1.82/sh).","Pursuing divestiture of CertainT platform; targeting 15% opex reduction vs FY2024, expected by Q2 FY2025.","Judith Murrah promoted to President (salary increased to $400K); Clay Shorrock named President of LineaRx subsidiary.","GMP manufacturing facility buildout to complete by Jan 9, 2025; annual revenue capacity $4M-$16M depending on product mix.","Raised $5.8M net in registered direct offering on Oct 31, 2024; cash ~$10.1M as of Nov 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199923,"accession_number":"0001104659-24-117025","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Applied DNA Sciences receives Nasdaq deficiency notice for minimum bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company's common stock closed below $1.00 for 31 consecutive business days from Sept 27 to Nov 11, 2024.","Company has 180 calendar days until May 12, 2025 to regain compliance; needs $1.00 closing bid for 10 consecutive days.","Company is obligated under a prior securities purchase agreement to effect a reverse stock split within 30 days of stockholder approval if compliance not regained.","Company intends to implement a reverse stock split to remedy the bid price deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199922,"accession_number":"0001104659-24-115342","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Applied DNA Sciences reduces stockholder quorum to one-third","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted Certificate of Amendment to Bylaws effective November 7, 2024.","Quorum for stockholder meetings reduced from majority to one-third (1/3) of issued and outstanding shares.","CEO granted authority to adjourn any stockholder meeting.","No change to fiscal year; only governance adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199921,"accession_number":"0001104659-24-112750","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Applied DNA Sciences prices $6.5M registered direct and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$6.5M from sale of 20.3M shares (or pre-funded warrants) at $0.32 per share.","Issues Series C and D warrants to purchase 20.3M shares each, both exercisable at $0.32 after stockholder approval.","Series D exercise price resets to lower of $0.32 or lowest VWAP around a future reverse split, floor $0.0634.","Amends existing Series A warrants to set floor price at $0.20 for price protection provisions.","Net proceeds for therapeutic DNA production services development and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215936,"accession_number":"0001104659-24-104332","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"APDN shareholders approve reverse stock split authorization (1:5-1:50) and warrant exercisability","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six directors elected: Hayward (2.36M for, 0.91M withheld), Catell (2.38M for), Ceccoli (2.38M for), Shamash (2.38M for), Simon (2.38M for), Shaheen (2.38M for).","Ratification of Marcum LLP as auditor: 4.41M for, 0.65M against, 0.15M abstain.","Board granted 12-month authority to implement reverse stock split between 1:5 and 1:50; 3.70M for, 1.23M against, 0.28M abstain.","Approval of warrant exercisability and underlying common stock issuance (May 2024 offering): 2.22M for, 0.99M against, 0.06M abstain, 1.94M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215935,"accession_number":"0001104659-24-100839","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Applied DNA regains Nasdaq minimum bid price compliance; delisting risk removed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on Sept 17, 2024 that closing bid price was ≥$1.00 for 20 consecutive business days through Sept 16, 2024.","Previously notified on July 12, 2024 of non-compliance with the $1.00 minimum bid price rule under Listing Rule 5550(a)(2).","Regained compliance after closing bid price remained at or above $1.00 for the 20-business-day period; matter is now closed.","No further action required; common stock (APDN) remains listed on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215934,"accession_number":"0001104659-24-087280","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Applied DNA Sciences Q3 FY2024 revenue falls 72% YoY to $798K; operating loss widens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $798K for Q3 ended June 30, 2024, down from $2.9M, driven by end of CUNY COVID testing contract.","Gross profit $245K (31% margin) vs $1.3M (44%); operating loss $3.3M vs $2.9M year ago.","Adjusted EBITDA negative $3.2M vs negative $2.1M; cash position $10.4M up from $7.2M after $10.5M public offering.","LineaRx GMP facility on track for FY24 year-end launch; Linea IVT GMP runs expected early CY25.","Multi-year certainT agreement with Indus Group post-close; TR8 PGx testing capacity set at potential $25M annual revenue."],"consensus_eps_estimate":-260.1,"consensus_eps_actual":-2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":2618313.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215933,"accession_number":"0001104659-24-085391","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Applied DNA Sciences special meeting fails due to lack of quorum; warrant approval deferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Aug 2, 2024 had 4,056,202 shares present, below required majority; adjourned without action.","Proposal sought stockholder approval to exercise Series A and B warrants from May 2024 public offering.","Without approval, company must call a subsequent meeting to seek warrant stockholder approval.","Series Warrants remain unexercisable until Nasdaq-required shareholder approval is obtained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215932,"accession_number":"0001104659-24-079875","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"APDN receives Nasdaq delisting notice for bid price non-compliance; plans reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified APDN on July 12, 2024, that its common stock failed to maintain minimum $1.00 bid price for 30 consecutive business days.","APDN has 180 calendar days, until Jan 8, 2025, to regain compliance by closing at $1.00 for 10 consecutive business days.","If non-compliance continues, APDN may request a second 180-day period by meeting other listing standards and effecting a reverse stock split.","Company intends to implement reverse stock split as required by outstanding Series Warrants unless bid price is regained by Jan 8, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235410,"accession_number":"0001104659-24-076311","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"APDN receives Nasdaq compliance confirmation for equity rule; future delisting risk if not maintained","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed compliance with stockholders' equity requirement of at least $2.5M on June 27, 2024.","Based on Form 8-K from June 18, 2024; no immediate delisting.","If next periodic report fails to show compliance, Nasdaq may initiate delisting; Company can appeal.","Ongoing monitoring required; potential future delisting risk highlighted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235409,"accession_number":"0001104659-24-072876","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Applied DNA Sciences believes it regained Nasdaq minimum equity compliance after $10.8M offering","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice May 16, 2024 for stockholders' equity of -$175,385 vs. $2.5M minimum requirement.","Closed public offering May 29, 2024, raising approximately $10.8M in net proceeds from common stock and warrants.","Company now believes it meets Nasdaq Listing Rule 5550(b)(1) stockholders' equity requirement.","Nasdaq will continue monitoring; non-compliance at next periodic report may lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235408,"accession_number":"0001104659-24-066098","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Applied DNA Sciences prices $12M public offering of units with warrants subject to stockholder approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$12M from 9,230,769 units at $1.30 per unit (or $1.2999 with pre-funded warrant).","Each unit includes one share (or pre-funded warrant) plus two Series A and B warrants exercisable at $1.99 after stockholder approval.","Proceeds to fund therapeutic DNA production services, MDx testing, and general corporate purposes.","Offering closed May 29, 2024; Craig-Hallum and Laidlaw & Co. acted as placement agents.","Warrants are not exercisable until stockholder approval obtained; special meeting planned within 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235407,"accession_number":"0001104659-24-062618","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Applied DNA Sciences receives Nasdaq equity deficiency notice; equity negative $175K","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["As of March 31, 2024, stockholders' equity was negative $175,385, below the $2.5M minimum for Nasdaq Capital Market.","Company must submit a compliance plan by July 1, 2024 to regain compliance with Nasdaq Listing Rule 5550(b)(1).","Nasdaq may grant up to 180-day extension if plan accepted; no guarantee of acceptance or eventual compliance.","Letter has no immediate effect on listing; company is evaluating options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235406,"accession_number":"0001104659-24-059893","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Applied DNA Q2 revenue down 79% to $930k; operating loss widens to $3.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $930k vs $4.4M YoY; COVID testing contract with CUNY ended June 2023.","Gross profit declined to $296k (32% margin) from $1.8M (41%) YoY.","Operating loss $3.6M vs $2.7M YoY; adjusted EBITDA -$3.3M.","Cash $3.1M as of March 31, 2024, down from $7.2M at Sept 30, 2023.","Effected 1-for-20 reverse stock split on April 25, 2024; regained Nasdaq bid price compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":1820795.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235405,"accession_number":"0001104659-24-055368","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Applied DNA provides investor presentation with no new material disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed a presentation for investor use; no financial results or guidance included.","Presentation emphasizes cell-free enzymatic DNA platform for genetic medicines.","No specific data on revenue, contracts, or milestones disclosed in the filing.","Risks highlighted include history of net losses and going concern doubt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235401,"accession_number":"0001104659-24-050524","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K/A","filed_at":"2024-04-23T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Applied DNA Sciences files amended 8-K to update CUSIP for 1:20 reverse stock split effective April 25, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:20 ratio approved; effective 12:01 a.m. ET on April 25, 2024.","CUSIP number for common stock changed to 03815U409.","Fractional shares will be rounded up to the nearest whole share.","No change to Nasdaq ticker symbol APDN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235404,"accession_number":"0001104659-24-050056","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Applied DNA to effect 1-for-20 reverse stock split on April 25, 2024 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:20 ratio effective 12:01 a.m. ET on April 25, 2024; shares trade split-adjusted at market open.","Outstanding shares reduced from ~17.26M to ~863,000; par value unchanged at $0.001 per share.","Stockholders approved reverse split at April 15 special meeting (ratio range 1:5 to 1:50); Board set final ratio 1:20.","Split intended to regain Nasdaq minimum bid price compliance of $1.00 per share.","No fractional shares issued; fractional shares rounded up to nearest whole share; new CUSIP is 03815U409."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2769493.1419999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-04-22T23:59:59+00:00|235404"}